Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age

Haralambieva, Iana H.; Ovsyannikova, Inna G.; Kennedy, Richard B.; Goergen, Krista M.; Grill, Diane E.; Chen, Min Hsin; Hao, Lijuan; Icenogle, Joseph P.

doi:10.1016/j.vaccine.2019.11.004

Cited by 15 publications

(19 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All demographic and clinical variables of study participants have been described previously [16]. Briefly, the study sample consisted of 56 females enrolled in the low‐antibody group and 53 females enrolled in the high‐antibody group based on their screening rubella‐specific IgG antibody titer.…”

Section: Resultsmentioning

confidence: 99%

“…The median time from second rubella vaccination to enrollment in this study was 22.9 years (IQR, 18.4, 25.3). We did not observe statistically significant differences in vaccine history or demographic/clinical variables between the two groups [16]. The baseline rubella‐specific neutralizing antibody titer (geometric mean with 95% confidence interval [GM, 95% CI] in NT 50 ) was 41.8 (17.4, 100.3) for the low‐antibody responder group and 162.2 (41.6, 632.6) for the high‐antibody responder group.…”

Section: Resultsmentioning

confidence: 99%

“…The peak (Day 28) neutralizing antibody titer after a third dose of MMR vaccine was 195.3 (53.3, 715.8) for the low responders and 309.9 (95.0, 1011.0) for the high responders, with no seronegative individuals. The observed differences between the two groups were statistically significant ( p ‐value = 6.1 × 10 ‐16 for the Baseline comparison and p ‐value = 5.6 × 10 ‐04 for the comparison at Day 28) [16]. The frequencies of rubella‐specific memory B cells at Baseline (quantified in an ELISPOT assay in SFUs/2 × 10 5 cells/peripheral blood mononuclear cells [PBMCs] and presented as GM, 95% CI) were 6.17 (1.31, 28.99) for the low‐responder group and 10.54 (2.43, 45.79) for the high‐responder group ( p ‐value = 0.002).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Transcriptional signatures associated with rubella virus‐specific humoral immunity after a third dose of MMR vaccine in women of childbearing age

et al. 2021

Self Cite

View full text Add to dashboard Cite

Multiple factors linked to host genetics/inherent biology play a role in interindividual variability in immune response outcomes after rubella vaccination. In order to identify these factors, we conducted a study of rubella‐specific humoral immunity before (Baseline) and after (Day 28) a third dose of MMR‐II vaccine in a cohort of 109 women of childbearing age. We performed mRNA‐Seq profiling of PBMCs after rubella virus in vitro stimulation to delineate genes associated with post‐vaccination rubella humoral immunity and to define genes mediating the association between prior immune response status (high or low antibody) and subsequent immune response outcome. Our study identified novel genes that mediated the association between prior immune response and neutralizing antibody titer after a third MMR vaccine dose. These genes included the following: CDC34; CSNK1D; APOBEC3F; RAD18; AAAS; SLC37A1; FAS; and JAK2. The encoded proteins are involved in innate antiviral response, IFN/cytokine signaling, B cell repertoire generation, the clonal selection of B lymphocytes in germinal centers, and somatic hypermutation/antibody affinity maturation to promote optimal antigen‐specific B cell immune function. These data advance our understanding of how subjects’ prior immune status and/or genetic propensity to respond to rubella/MMR vaccination ultimately affects innate immunity and humoral immune outcomes after vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Transcriptional signatures associated with rubella virus‐specific humoral immunity after a third dose of MMR vaccine in women of childbearing age

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, in the same period, several European countries have registered a decreasing trend in their vaccination coverages, with alarming outbreaks of VPDs [ 41 , 42 ]. Although the global immunization strategy involves people of all ages, pregnant women and their children are considered to be two major groups on which to focus efforts and interventions from public health professionals [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…As vaccine-preventable diseases (VPDs) can negatively affect fertility and pregnancy outcomes, vaccinations against Measles, Mumps, Rubella, Varicella and Human Papillomavirus (HPV) are indicated for women of childbearing age [ 14 , 15 ]. The high risks arising from maternal infections also make it necessary to vaccinate women against Measles-Mumps-Rubella (MMR) and Varicella in anticipation of pregnancy.…”

Section: Introductionmentioning

confidence: 99%

Vaccination Status of Mothers and Children from the ‘Mamma & Bambino’ Cohort

et al. 2021

View full text Add to dashboard Cite

According to the evidence demonstrating vaccines’ safety and effectiveness in anticipation of and during pregnancy, several countries have established immunization programs during the periconceptional period. Here, we evaluated vaccination status among 220 mother–child pairs, using data from the ‘Mamma & Bambino’ cohort. The self-reported data were evaluated at delivery, and with planned follow-ups at 1–2 years after delivery. In general, we noted that the vaccination status among the women was heterogeneous, ranging from 8.3% (vaccine against Human Papillomavirus, HPV) to 65.6% (vaccine against Diphtheria Tetanus and Pertussis, DTaP). Excluding the women who contracted the diseases in the past, the main ground for refusal was the lack of information. We also demonstrated that increasing age was associated with higher odds of not being vaccinated against Measles-Mumps-Rubella (MMR; OR = 1.12; 95% CI = 1.04-1.21; p = 0.004), HPV (OR = 1.20; 95% CI = 1.08-1.33; p = 0.001) and DTaP (OR =1.09; 95% CI = 1.01-1.18; p = 0.040). As expected, we showed that the proportion of newborns vaccinated with the Hexavalent and Pneumococcal vaccines was high (99.5% and 98.6%, respectively), while the vaccination coverage against MMRV did not reach the auspicated threshold (84.1%). Overall, these results underlined the need for the improvement of women’s knowledge about the recommendations for vaccination, especially during pregnancy.

show abstract

Rubella Virus

Maldonado¹,

Shetty²

2023

Principles and Practice of Pediatric Infectious Diseases

View full text Add to dashboard Cite

Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age

Cited by 15 publications

References 54 publications

Transcriptional signatures associated with rubella virus‐specific humoral immunity after a third dose of MMR vaccine in women of childbearing age

Transcriptional signatures associated with rubella virus‐specific humoral immunity after a third dose of MMR vaccine in women of childbearing age

Vaccination Status of Mothers and Children from the ‘Mamma & Bambino’ Cohort

Rubella Virus

Contact Info

Product

Resources

About